Geode Capital Management’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
VCM
MCM
TSC
PCM
SS
Geode Capital Management's LUCD Position: Q1 2026 in Review
Geode Capital Management increased its Lucid Diagnostics (LUCD) stake by 11% in Q1 2026, buying an estimated $278K and bringing the position to 2,245,350 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3028.
Geode Capital Management first reported a position in LUCD in Q4 2021 and has held it in 18 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.
- Geode Capital Management held 2,245,350 shares of Lucid Diagnostics worth $2.58M as of Q1 2026.
- Geode Capital Management bought 218,523 Lucid Diagnostics shares in Q1 2026, an estimated $278K.
- Lucid Diagnostics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3028 holding.
- Geode Capital Management first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 18 quarters since.
- 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.